JP2022504620A5 - - Google Patents

Info

Publication number
JP2022504620A5
JP2022504620A5 JP2021519726A JP2021519726A JP2022504620A5 JP 2022504620 A5 JP2022504620 A5 JP 2022504620A5 JP 2021519726 A JP2021519726 A JP 2021519726A JP 2021519726 A JP2021519726 A JP 2021519726A JP 2022504620 A5 JP2022504620 A5 JP 2022504620A5
Authority
JP
Japan
Prior art keywords
compound
oxo
methyl
triazine
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021519726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504620A (ja
JP7595004B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/055689 external-priority patent/WO2020077123A1/en
Publication of JP2022504620A publication Critical patent/JP2022504620A/ja
Publication of JP2022504620A5 publication Critical patent/JP2022504620A5/ja
Priority to JP2024204381A priority Critical patent/JP2025041602A/ja
Application granted granted Critical
Publication of JP7595004B2 publication Critical patent/JP7595004B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021519726A 2018-10-12 2019-10-10 甲状腺ホルモン受容体ベータアゴニスト化合物 Active JP7595004B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024204381A JP2025041602A (ja) 2018-10-12 2024-11-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862745195P 2018-10-12 2018-10-12
US62/745,195 2018-10-12
PCT/US2019/055689 WO2020077123A1 (en) 2018-10-12 2019-10-10 Thyroid hormone receptor beta agonist compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024204381A Division JP2025041602A (ja) 2018-10-12 2024-11-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Publications (3)

Publication Number Publication Date
JP2022504620A JP2022504620A (ja) 2022-01-13
JP2022504620A5 true JP2022504620A5 (cg-RX-API-DMAC7.html) 2022-10-13
JP7595004B2 JP7595004B2 (ja) 2024-12-05

Family

ID=70161488

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519726A Active JP7595004B2 (ja) 2018-10-12 2019-10-10 甲状腺ホルモン受容体ベータアゴニスト化合物
JP2024204381A Pending JP2025041602A (ja) 2018-10-12 2024-11-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024204381A Pending JP2025041602A (ja) 2018-10-12 2024-11-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Country Status (9)

Country Link
US (2) US11203587B2 (cg-RX-API-DMAC7.html)
EP (1) EP3863635A4 (cg-RX-API-DMAC7.html)
JP (2) JP7595004B2 (cg-RX-API-DMAC7.html)
CN (1) CN112839655B (cg-RX-API-DMAC7.html)
AR (1) AR116694A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019357618B2 (cg-RX-API-DMAC7.html)
MA (1) MA53868A (cg-RX-API-DMAC7.html)
TW (2) TWI884745B (cg-RX-API-DMAC7.html)
WO (1) WO2020077123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
WO2021244582A1 (zh) * 2020-06-02 2021-12-09 成都康弘药业集团股份有限公司 新型甲状腺激素β受体激动剂
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
JP2024510935A (ja) * 2021-03-03 2024-03-12 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
CA2473162A1 (en) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
FR2882750B1 (fr) * 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
ATE480524T1 (de) * 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
FR2933979B1 (fr) 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
KR101396606B1 (ko) 2009-04-20 2014-05-16 미쓰비시 타나베 파마 코퍼레이션 신규 갑상선 호르몬 β 수용체 작동약
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
EA023521B1 (ru) * 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN107074823B (zh) * 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
WO2020041741A1 (en) 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN119552152A (zh) 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
WO2020239076A1 (zh) 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用

Similar Documents

Publication Publication Date Title
JP2022544714A5 (cg-RX-API-DMAC7.html)
WO2018013597A4 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
RU2655914C2 (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2014509647A5 (cg-RX-API-DMAC7.html)
CN114222740A (zh) 新型极光激酶抑制剂及其用途
JP2022512482A5 (cg-RX-API-DMAC7.html)
TWI801517B (zh) 經取代的2-吡啶酮三環化合物、其類似物及其使用方法
JP2021500394A5 (cg-RX-API-DMAC7.html)
JP7811768B2 (ja) ピロール化合物
JP2021514001A5 (cg-RX-API-DMAC7.html)
JP2017512789A (ja) ジヒドロピリミジン化合物及び医薬におけるその適用
RU2011147232A (ru) Производное карбоновой кислоты
JP2016505619A5 (cg-RX-API-DMAC7.html)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2015516420A5 (cg-RX-API-DMAC7.html)
JP2023531709A5 (cg-RX-API-DMAC7.html)
JP2015514063A5 (cg-RX-API-DMAC7.html)
JP2016503785A5 (cg-RX-API-DMAC7.html)
JP2017529389A5 (cg-RX-API-DMAC7.html)
JP2017523223A5 (cg-RX-API-DMAC7.html)
CA2796826A1 (en) Bifunctional quinoline derivatives
JP2013526520A5 (cg-RX-API-DMAC7.html)
JP2008537930A5 (cg-RX-API-DMAC7.html)
RU2016129189A (ru) Производные 3-(5-хлор-2-оксобензо[d]оксазол-3(2н)-ил)пропановой кислоты в качестве кмо ингибиторов